arrow
A

Arsela Prelaj

Fondazione IRCCS Istituto Nazionale dei Tumori
H指数:26
被引数:2,623

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Chronobiological Prognostic Model for Resected Stage I Non-Small-Cell Lung Cancer

基于昼夜节律的预后模型用于切除的I期非小细胞肺癌

Cancers
IF4.4
2026-10-050
OA
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

可解释AI决策支持工具的临床可用性及非小细胞肺癌中多模态模型的评估

2026-09-130
OAAI
AI-based augmentation of oncology clinical trials

基于人工智能的肿瘤学临床试验增强

2026-08-070
PRE
Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study

可解释机器学习预测转移性肾细胞癌免疫治疗结局——Meet-URO 15-AI研究

2026-07-020
OAAI
Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50%

网络分析预测PD-L1<50%的晚期NSCLC对pembrolizumab的应答

2026-03-260
OA
ESMO Basic Requirements for AI-based Biomarkers In Oncology (EBAI)

ESMO对基于AI的肿瘤学生物标志物的基本要求 (EBAI)

2025-11-180
OAAI
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors

ESMO-ESTRO关于将放射疗法与免疫检查点抑制剂、VEGF(R)抑制剂或多靶点酪氨酸激酶抑制剂联合使用的安全性共识声明

2025-09-260
PRE
ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy

ESMO-ESTRO评估放射治疗与靶向癌症治疗或免疫治疗联合应用相互作用及安全性的框架

2025-07-010
PRE
Unleashing precision: A review of targeted approaches in pleural mesothelioma (vol 203C, 104481, 2024)
2024-12-010
PRE
Unleashing precision: A review of targeted approaches in pleural mesothelioma
2024-11-012
OAAI
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)

ramucirumab联合卡铂和紫杉醇治疗未治疗的转移性胸腺癌的疗效和安全性: RELEVENT II期试验 (NCT03921671)

2024-09-012
OA
Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy

数字病理学预测接受免疫治疗的转移性非小细胞肺癌患者的PD-L1表达

2024-09-010
PRE
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer
2024-05-014
PRE
Dissecting circulating tumor cells phenotype in a cohort of locally advanced non-small cell lung cancer patients undergoing neoadjuvant chemotherapy
2024-03-220
PRE
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research
2024-03-011
OAAI
Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems*
HELIYON
IF3.6
2024-01-0111
OAAI
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review

免疫肿瘤学中预测生物标志物发现的人工智能: 系统综述

2024-01-0138
OAAI